Secreted Matrix Metalloproteinase-9 of Proliferating Smooth Muscle Cells as a Trigger for Drug Release from Stent Surface Polymers in Coronary Arteries.
暂无分享,去创建一个
A. Schmidt | Timo Glatter | J. Huwyler | D. Witzigmann | Fabiola Porta | J. Hussner | D. Gliesche | Henriette E. Meyer zu Schwabedissen
[1] K. Garratt. Duration of Dual Anti-Platelet Therapy Post-Percutaneous Intervention: Is There A Correct Amount of Time? , 2015, Progress in cardiovascular diseases.
[2] H. Kroemer,et al. Tailored surface design of biodegradable endovascular implants by functionalization of poly (L-lactide) with elastin-like proteins , 2015 .
[3] N. Artzi,et al. Tuning of Collagen Scaffold Properties Modulates Embedded Endothelial Cell Regulatory Phenotype in Repair of Vascular Injuries In Vivo , 2015, Advanced healthcare materials.
[4] Mei-xiang Xiang,et al. Endothelial Progenitor Cells and In-stent Restenosis. , 2015, Current stem cell research & therapy.
[5] F. Prati,et al. Comparison of Strut Coverage at 6 Months by Optical Coherence Tomography With Everolimus-Eluting Stenting of Bare-Metal Stent Restenosis Versus Stenosis of Nonstented Atherosclerotic Narrowing (from the DESERT Study). , 2015, The American journal of cardiology.
[6] Deniz A. Bölükbas,et al. Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors. , 2015, ACS nano.
[7] L. Matrisian,et al. New tools for the quantitative assessment of prodrug delivery and neurotoxicity. , 2015, Neurotoxicology.
[8] E. Galliera,et al. Matrix metalloproteinases as biomarkers of disease: updates and new insights , 2015, Clinical chemistry and laboratory medicine.
[9] G. Hamed,et al. Clinical Relevance of Matrix Metalloproteinase 9 in Patients With Acute Coronary Syndrome , 2015, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[10] P. Serruys,et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial , 2015, The Lancet.
[11] C. Hamm,et al. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. , 2014, Journal of the American College of Cardiology.
[12] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[13] Alexander Schmidt,et al. Evaluation of data-dependent and -independent mass spectrometric workflows for sensitive quantification of proteins and phosphorylation sites. , 2014, Journal of proteome research.
[14] Sean McGinty,et al. A decade of modelling drug release from arterial stents. , 2014, Mathematical biosciences.
[15] P. Jüni,et al. Short versus long duration of DAPT after DES implantation: a meta-analysis. , 2014, Journal of the American College of Cardiology.
[16] R. Kornowski,et al. Long-term comparative analysis from an all-comer cohort of coronary patients treated using first- and second-generation drug-eluting stents. , 2014, The Journal of invasive cardiology.
[17] Katie M. Reindl,et al. MMP-9 Responsive PEG Cleavable Nanovesicles for Efficient Delivery of Chemotherapeutics to Pancreatic Cancer , 2014, Molecular pharmaceutics.
[18] M. Hacker,et al. Matrix metalloproteinase 9 (MMP-9) mediated release of MMP-9 resistant stromal cell-derived factor 1α (SDF-1α) from surface modified polymer films. , 2014, ACS applied materials & interfaces.
[19] K. Schmitz,et al. Cell-specific expression of uptake transporters--a potential approach for cardiovascular drug delivery devices. , 2014, Molecular pharmaceutics.
[20] V. Kocka,et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’ , 2014, European heart journal.
[21] K. Filion,et al. Late and very late stent thrombosis in patients with second-generation drug-eluting stents. , 2013, The Canadian journal of cardiology.
[22] L. Joosten,et al. Towards a role of interleukin-32 in atherosclerosis. , 2013, Cytokine.
[23] Chieh-Hsi Wu,et al. Demethoxycurcumin, a major active curcuminoid from Curcuma longa, suppresses balloon injury induced vascular smooth muscle cell migration and neointima formation: an in vitro and in vivo study. , 2013, Molecular nutrition & food research.
[24] Y. St-Pierre,et al. Epigenetic regulation of mmp-9 gene expression , 2013, Cellular and Molecular Life Sciences.
[25] L. Matrisian,et al. Synthesis and in vitro efficacy of MMP9-activated NanoDendrons. , 2013, Molecular pharmaceutics.
[26] H. Kroemer,et al. In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release , 2013, Journal of Materials Science: Materials in Medicine.
[27] P. E. Van den Steen,et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade , 2013, Critical reviews in biochemistry and molecular biology.
[28] G. Opdenakker,et al. Zymography methods for visualizing hydrolytic enzymes , 2013, Nature Methods.
[29] J. Montaner,et al. The angiogenic gene profile of circulating endothelial progenitor cells from ischemic stroke patients , 2013, Vascular cell.
[30] H. Leu,et al. Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction , 2013, Coronary artery disease.
[31] D. Faxon,et al. Very late stent thrombosis: current concepts , 2012, Current opinion in cardiology.
[32] R. Aebersold,et al. Large-scale quantitative assessment of different in-solution protein digestion protocols reveals superior cleavage efficiency of tandem Lys-C/trypsin proteolysis over trypsin digestion. , 2012, Journal of proteome research.
[33] A. Jakab,et al. Time course of endothelium-dependent and -independent coronary vasomotor response to coronary balloons and stents. Comparison of plain and drug-eluting balloons and stents. , 2012, JACC. Cardiovascular interventions.
[34] A. Newby. Matrix metalloproteinase inhibition therapy for vascular diseases. , 2012, Vascular pharmacology.
[35] G. Stone,et al. Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy , 2012, Journal of Thrombosis and Thrombolysis.
[36] V. Mechírová,et al. Matrix Metalloproteinases and Their Role in Oncogenesis: A Review , 2012, Oncology Research and Treatment.
[37] K. Okumura,et al. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. , 2011, Hypertension.
[38] Jian Li,et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. , 2011, Cancer research.
[39] Y. Jo,et al. Plaque Rupture is a Determinant of Vascular Events in Carotid Artery Atherosclerotic Disease: Involvement of Matrix Metalloproteinases 2 and 9 , 2011, Journal of clinical neurology.
[40] Masataka Nakano,et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. , 2011, Journal of the American College of Cardiology.
[41] Gerald T Miwa,et al. Bioactivation of drugs: risk and drug design. , 2011, Annual review of pharmacology and toxicology.
[42] Patrick W Serruys,et al. Coronary stents: looking forward. , 2010, Journal of the American College of Cardiology.
[43] W. Stetler-Stevenson,et al. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. , 2010, Seminars in cancer biology.
[44] M. Washburn,et al. Refinements to label free proteome quantitation: how to deal with peptides shared by multiple proteins. , 2010, Analytical chemistry.
[45] Tycho Heimbach,et al. Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.
[46] P. Seifert,et al. Early vascular response to overlapped paclitaxel-eluting stents in swine coronary arteries. , 2007, Cardiovascular revascularization medicine : including molecular interventions.
[47] R. Jaffe,et al. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. , 2007, Journal of the American College of Cardiology.
[48] Michael Joner,et al. Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[49] Michael Joner,et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.
[50] T. Htay,et al. Drug-Eluting Stent: A Review and Update , 2005, Vascular health and risk management.
[51] D. J. Moliterno. Healing Achilles--sirolimus versus paclitaxel. , 2005, The New England journal of medicine.
[52] L. Young,et al. Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model , 2005, Leukemia.
[53] G. Trainor,et al. Matrix metalloproteinase–activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity , 2005, Molecular Cancer Therapeutics.
[54] R. Virmani,et al. Extracellular Matrix Changes in Stented Human Coronary Arteries , 2004, Circulation.
[55] M. Rothman,et al. Antiproliferative coatings for the treatment of coronary heart disease:. what are the targets and which are the tools? , 2003, Journal of interventional cardiology.
[56] Jeffrey W. Smith,et al. A Residue in the S2 Subsite Controls Substrate Selectivity of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9* , 2003, Journal of Biological Chemistry.
[57] Rossella Fattori,et al. Drug-eluting stents in vascular intervention , 2003, The Lancet.
[58] Mary E. Russell,et al. TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.
[59] A. Cho,et al. Matrix Metalloproteinase-9 Is Necessary for the Regulation of Smooth Muscle Cell Replication and Migration After Arterial Injury , 2002, Circulation research.
[60] P. Serruys,et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.
[61] K. Schrör,et al. Factor Xa Releases Matrix Metalloproteinase-2 (MMP-2) From Human Vascular Smooth Muscle Cells and Stimulates the Conversion of Pro–MMP-2 to MMP-2: Role of MMP-2 in Factor Xa–Induced DNA Synthesis and Matrix Invasion , 2002, Circulation research.
[62] J. Deux,et al. Differential Expression of Matrix Metalloproteinases After Stent Implantation and Balloon Angioplasty in the Hypercholesterolemic Rabbit , 2001, Circulation.
[63] M. Radomski,et al. Differential Regulation of Platelet Aggregation by Matrix Metalloproteinases-9 and -2 , 1999, Thrombosis and Haemostasis.
[64] R. Ross. Atherosclerosis is an inflammatory disease , 1999 .
[65] G. Giannelli,et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. , 1997, Science.
[66] R. Virmani,et al. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. , 1994, Journal of the American College of Cardiology.
[67] W Rutsch,et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.
[68] J. O'Connell,et al. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. , 1994, The Journal of biological chemistry.
[69] M. Leon,et al. Emergent Use of Balloon‐Expandable Coronary Artery Stenting for Failed Percutaneous Transluminal Coronary Angioplasty , 1992, Circulation.
[70] Larry S. Dean,et al. Intracoronary Stenting for Acute and Threatened Closure Complicating Percutaneous Transluminal Coronary Angioplasty , 1992, Circulation.
[71] J. Woessner,et al. Matrix metalloproteinases and their inhibitors in connective tissue remodeling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[72] B Meier,et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. , 1991, The New England journal of medicine.
[73] Pitter F. Huesgen,et al. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. , 2016, Matrix biology : journal of the International Society for Matrix Biology.
[74] P. Serruys,et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary ste , 2015, JACC. Cardiovascular interventions.
[75] M. Alavi,et al. Expression of metalloproteinases and its inhibitor in later stage of rabbit neointima development. , 2001, International journal of molecular medicine.
[76] P. Serruys,et al. Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. , 1993, Journal of the American College of Cardiology.
[77] G. Elion. Acyclovir: Discovery, mechanism of action, and selectivity , 1993, Journal of medical virology.